Sign inJoin waitlistJoin the waitlist

Stephanie Fetzko

Director, Adolescent and Young Adult Program, Cancer and Hematology Center · Baylor College of Medicine

Credentials: · · ·

History

Adolescent and Young Adult Program · Baylor College of Medicine
Present
Oncofertility Program · Baylor College of Medicine
Present
Baylor College of Medicine
Present

University of Michigan
2017–2018
Pediatric Hematology/Oncology
Baylor College of Medicine
2014–2017
Pediatrics
2011–2014
Duke University School of Medicine
2007–2011
University of Miami

Research

Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine
European Journal of Cancer · 2016 · 20 citations
Soft Tissue and Visceral Organ Sarcomas With BCOR Alterations
Journal of Pediatric Hematology/Oncology · 2022 · 15 citations
Is Detection of Relapse by Surveillance Imaging Associated With Longer Survival in Patients With Rhabdomyosarcoma?
Journal of Pediatric Hematology/Oncology · 2022 · First of 14 authors · 10 citations

Bhuvana Setty
2 papers
David Walterhouse
2 papers
Douglas Hawkins
2 papers
HR
Heidi Russell
2 papers
Lauren Nicholls
2 papers
Mehmet Okcu
2 papers · 2 as a fellow
Adriana Sheridan
1 paper
Angshumoy Roy
1 paper
Anish Butala
1 paper · 1 as a resident
Araz Marachelian
1 paper
AA
Asra Ahmed
1 paper
Brian Weiss
1 paper

Clinical trials

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
Principal investigator · Recruiting · Phase 1
Baylor College of Medicine
2026–2044
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
Principal investigator · Terminated · Phase 1
EpicentRx, Inc.
2023–2024
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029